PV Bulletin

Field Safety Notice: Bolton Medical RelayPro Thoracic Stent-Graft System (NBS)

MHRA issued field safety notice for Bolton Medical RelayPro Thoracic Stent-Graft System (model 28-N4-XX-XXX-XXS) requiring users to follow specific actions in the FSN document.

Primary source: Medicines and Healthcare products Regulatory Agency (MHRA)

PV Impact Brief

Urgency: HighConfidence: high

What changed

MHRA published a field safety notice for the RelayPro Thoracic Stent-Graft System (NBS) on 8 June 2026, detailing required user actions.

Why it matters

This FSN indicates a potential safety issue with the device that may impact patient safety and requires prompt attention from users to mitigate risk.

Action needed

Verify inventory of affected RelayPro Thoracic Stent-Graft System lots (model 28-N4-XX-XXX-XXS) and implement actions per the FSN document.

Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal ManagementLabeling
Owner

Regulatory Intelligence Lead

Review cadence

weekly

Regulatory action details

Action type
Field Safety Notice (FSN)
Publication date
2026-06-08
Safety issue
Field safety notice regarding the RelayPro Thoracic Stent-Graft System (NBS), MHRA reference 39747013.

Affected products

  • RelayPro Thoracic Stent-Graft System (NBS)
    Bolton Medical

PV internal implications

Users should follow the specific actions provided in the FSN document for the RelayPro system.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 8, 2026

Full briefing

Practical implication

Verify inventory of affected RelayPro Thoracic Stent-Graft System lots (model 28-N4-XX-XXX-XXS) and implement actions per the FSN document.

MHRA field safety notice (reference 39747013) for the RelayPro Thoracic Stent-Graft System (NBS) from Bolton Medical instructs users to follow the outlined corrective actions.

What changed: MHRA published a field safety notice for the RelayPro Thoracic Stent-Graft System (NBS) on 8 June 2026, detailing required user actions.

Why it matters: This FSN indicates a potential safety issue with the device that may impact patient safety and requires prompt attention from users to mitigate risk.

Practical implication: Verify inventory of affected RelayPro Thoracic Stent-Graft System lots (model 28-N4-XX-XXX-XXS) and implement actions per the FSN document.

View original source

Published from the Firecrawl agent regulatory extraction pipeline.

#Field Safety Notice#Medical Device#Stent-Graft#Bolton Medical#MHRA#Field Safety Notice (FSN)#Medicines and Healthcare products Regulatory Agency (MHRA)#other

Related updates for your role

publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact4 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward